Immunome Inc. — Director's Dealing 2020

Oct 2, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-01

Reporting Person: Widlitz Michael (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (51315)		Direct

Footnotes

F1: Each share of Series A Preferred Convertible Stock is convertible at any time at the option of the holder, without payment of additional
consideration, into Common Stock, on a one-for-one basis, has no expiration date and will automatically convert into shares of Common Stock
upon the closing of the Issuer's initial public offering.